Cargando…
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study
BACKGROUND: This post hoc analysis assessed the safety, tolerability and effectiveness of long-term treatment with aripiprazole adjunctive to either bupropion or selective serotonin reuptake inhibitors (SSRIs)/serotonin–norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive dis...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119176/ https://www.ncbi.nlm.nih.gov/pubmed/25037144 http://dx.doi.org/10.1186/1756-0500-7-459 |
_version_ | 1782328927083036672 |
---|---|
author | Clayton, Anita H Baker, Ross A Sheehan, John J Cain, Zachary J Forbes, Robert A Marler, Sabrina Vogel Marcus, Ronald Berman, Robert M Thase, Michael E |
author_facet | Clayton, Anita H Baker, Ross A Sheehan, John J Cain, Zachary J Forbes, Robert A Marler, Sabrina Vogel Marcus, Ronald Berman, Robert M Thase, Michael E |
author_sort | Clayton, Anita H |
collection | PubMed |
description | BACKGROUND: This post hoc analysis assessed the safety, tolerability and effectiveness of long-term treatment with aripiprazole adjunctive to either bupropion or selective serotonin reuptake inhibitors (SSRIs)/serotonin–norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD). METHODS: Data from de novo patients (did not participate in 2 previous studies) in a 52-week, open-label safety study of adjunctive aripiprazole after documented inadequate response to 1–4 antidepressant treatments (ADTs; SSRI, SNRI, or bupropion) were analyzed post hoc. Assessments included safety and tolerability, sexual functioning (Massachusetts General Hospital Sexual Functioning Inventory [MGH-SFI]) and Clinical Global Impressions–Severity (CGI-S). RESULTS: Forty-seven patients received bupropion plus aripiprazole and 245 received an SSRI/SNRI plus aripiprazole; 19 (40.4%) and 78 (31.8%), respectively, completed 52 weeks of treatment, and 46 and 242, respectively, received ≥1 dose of study medication (safety sample). Median time to discontinuation (any reason) was 184.0 days. Overall, 97.8% of patients in the bupropion group and 93.8% in the SSRI/SNRI group experienced ≥1 adverse event. The most common treatment-emergent adverse events were fatigue (26.1%) and somnolence (21.7%) with bupropion and fatigue (23.6%) and akathisia (23.6%) with an SSRI/SNRI. Mean change in body weight at week 52 (observed cases) was +3.1 kg for bupropion and +2.4 kg for an SSRI/SNRI. Treatment-emergent, potentially clinically relevant abnormalities in fasting glucose occurred in 8.3% of patients with bupropion and 17.4% with an SSRI/SNRI; for abnormalities in fasting total cholesterol, the incidence was 25.0% and 34.7%, respectively. Mean (SE) change from baseline in fasting glucose was 1.4 (1.9) mg/dL with bupropion and 2.7 (1.5) mg/dL with an SSRI/SNRI. Baseline MGH-SFI item scores indicated less severe impairment with bupropion versus an SSRI/SNRI; in both groups most MGH-SFI items exhibited improvement at week 52. Mean CGI-S improvement at week 52 (last observation carried forward) was -1.4 with bupropion and -1.5 with an SSRI/SNRI (efficacy sample). CONCLUSIONS: There were no unexpected AEs with long-term adjunctive aripiprazole therapy when added to either bupropion or SSRIs/SNRIs, and symptom improvement was similar between ADT groups. Sexual functioning in patients with MDD on antidepressants was also modestly improved after adding aripiprazole. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00095745 (November 9, 2004). |
format | Online Article Text |
id | pubmed-4119176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41191762014-08-03 Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study Clayton, Anita H Baker, Ross A Sheehan, John J Cain, Zachary J Forbes, Robert A Marler, Sabrina Vogel Marcus, Ronald Berman, Robert M Thase, Michael E BMC Res Notes Research Article BACKGROUND: This post hoc analysis assessed the safety, tolerability and effectiveness of long-term treatment with aripiprazole adjunctive to either bupropion or selective serotonin reuptake inhibitors (SSRIs)/serotonin–norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD). METHODS: Data from de novo patients (did not participate in 2 previous studies) in a 52-week, open-label safety study of adjunctive aripiprazole after documented inadequate response to 1–4 antidepressant treatments (ADTs; SSRI, SNRI, or bupropion) were analyzed post hoc. Assessments included safety and tolerability, sexual functioning (Massachusetts General Hospital Sexual Functioning Inventory [MGH-SFI]) and Clinical Global Impressions–Severity (CGI-S). RESULTS: Forty-seven patients received bupropion plus aripiprazole and 245 received an SSRI/SNRI plus aripiprazole; 19 (40.4%) and 78 (31.8%), respectively, completed 52 weeks of treatment, and 46 and 242, respectively, received ≥1 dose of study medication (safety sample). Median time to discontinuation (any reason) was 184.0 days. Overall, 97.8% of patients in the bupropion group and 93.8% in the SSRI/SNRI group experienced ≥1 adverse event. The most common treatment-emergent adverse events were fatigue (26.1%) and somnolence (21.7%) with bupropion and fatigue (23.6%) and akathisia (23.6%) with an SSRI/SNRI. Mean change in body weight at week 52 (observed cases) was +3.1 kg for bupropion and +2.4 kg for an SSRI/SNRI. Treatment-emergent, potentially clinically relevant abnormalities in fasting glucose occurred in 8.3% of patients with bupropion and 17.4% with an SSRI/SNRI; for abnormalities in fasting total cholesterol, the incidence was 25.0% and 34.7%, respectively. Mean (SE) change from baseline in fasting glucose was 1.4 (1.9) mg/dL with bupropion and 2.7 (1.5) mg/dL with an SSRI/SNRI. Baseline MGH-SFI item scores indicated less severe impairment with bupropion versus an SSRI/SNRI; in both groups most MGH-SFI items exhibited improvement at week 52. Mean CGI-S improvement at week 52 (last observation carried forward) was -1.4 with bupropion and -1.5 with an SSRI/SNRI (efficacy sample). CONCLUSIONS: There were no unexpected AEs with long-term adjunctive aripiprazole therapy when added to either bupropion or SSRIs/SNRIs, and symptom improvement was similar between ADT groups. Sexual functioning in patients with MDD on antidepressants was also modestly improved after adding aripiprazole. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00095745 (November 9, 2004). BioMed Central 2014-07-18 /pmc/articles/PMC4119176/ /pubmed/25037144 http://dx.doi.org/10.1186/1756-0500-7-459 Text en Copyright © 2014 Clayton et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Clayton, Anita H Baker, Ross A Sheehan, John J Cain, Zachary J Forbes, Robert A Marler, Sabrina Vogel Marcus, Ronald Berman, Robert M Thase, Michael E Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study |
title | Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study |
title_full | Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study |
title_fullStr | Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study |
title_full_unstemmed | Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study |
title_short | Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study |
title_sort | comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119176/ https://www.ncbi.nlm.nih.gov/pubmed/25037144 http://dx.doi.org/10.1186/1756-0500-7-459 |
work_keys_str_mv | AT claytonanitah comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy AT bakerrossa comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy AT sheehanjohnj comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy AT cainzacharyj comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy AT forbesroberta comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy AT marlersabrinavogel comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy AT marcusronald comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy AT bermanrobertm comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy AT thasemichaele comparisonofadjunctiveuseofaripiprazolewithbupropionorselectiveserotoninreuptakeinhibitorsserotoninnorepinephrinereuptakeinhibitorsanalysisofpatientsbeginningadjunctivetreatmentina52weekopenlabelstudy |